Roche's Phase III trial on higher IV Ocrevus doses for relapsing MS did not meet its primary goal but showed similar disability progression rates to approved doses. Despite missing the endpoint, Ocrevus demonstrated clinically meaningful outcomes.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing